Covid 19 coronavirus: Kiwi tech could offer low-cost immunity test

By Jamie Morton
Kiwi-developed technology – using “synthetic paint” to coat the outside of our red blood cells – could offer a low-cost way to test for Covid-19 immunity. The test, carried out in a just-published, uses a clever platform pioneered by the Auckland University of Technology team of engineering professor Steve Henry

Filter research wows at Falling Walls

Auckland University of Technology’s Ankita Poudyal, winner of the 2018 Falling Walls Lab New Zealand, won third place in the international finale event held in Berlin on 8 November with her presentation ‘Breaking the Walls of Inefficient Filters’.

Watch Ankita Poudyal’s presentation here:

2017 Pickering Medal: Painting cells and surfaces with bio-paints for widespread beneficial use

Professor Stephen Henry has been awarded the Pickering Medal by the Royal Society Te Apārangi for his development and commercialisation of a surface-modification technology, called Kode™ Technology, which shows huge promise for therapeutic use including fighting cancer, reducing surgical implant infections and healing wounds

The cure for cancer may be closer than we think, all thanks to a Kiwi invention

Business is Boring is a weekly podcast series presented by The Spinoff in association with Callaghan Innovation. Host Simon Pound speaks with innovators and commentators focused on the future of New Zealand, with the interview available as both audio and a transcribed excerpt

KiwiNet Research Commercialisation Awards

2017 finalists showcase research driving innovation

Twelve finalists have been selected for the fifth annual KiwiNet Research Commercialisation Awards, designed to celebrate commercialisation success within New Zealand’s universities and Crown Research Institutes.

Alumni @ JLABS – Kode Biotech

Area of focus: Our focus is to get Kode Technology licensed broadly as a core component that enables the next generation of therapeutics, diagnostics and high value consumer products.
Commencement date: February, 2017
Location: JLABS@TMC

Kiwi-made technology could cure cancer

Lucy Warhurst
A New Zealand-made technology behind a promising breakthrough cancer treatment is about to get a major boost.

The Auckland engineering professor behind it has become the first Australasian to secure a spot in the world-leading Johnson and Johnson Innovation centre, JLABS, in Houston.

Infection fighter has global potential

Surgical implants can be life-changing. Millions of people across the globe have had their mobility restored due to hip or knee replacements, for example; their quality of life restored by a single operation. But there is a darker side to implants. Studies reveal up to 5 per cent of those who receive them suffer post-operative infections, ultimately leading to long-term hospitalisation, limb loss or even death.

Cure for cancer just around the corner

Stephen Henry took home the prize of Supreme Innovator award at the NZ Innovators Awards. His company Kode Biotech have created a cancer treatment using the human body’s own auto immune responses.

On Wednesday night, Kode Biotech won the Supreme Innovator Award and the Innovation in Health & Science award at the NZ Innovators Awards.

Kode Biotech has been focused on the development of cell surface membrane modification technology in the fight against tumours. Synthetic animal antigens are used to modify the cancer cell surface membrane and encourage the body’s natural immune response to attack the cancer tumour cells. Kode Biotech’s lipid technology will be used in Agalimmune’s clinical human trials of their cancer immunotherapy molecules in 2016.

March 2015, Kode Biotech Limited concluded two therapeutic agreements. The first, with a publicly listed French company (market cap €200 million) will allow collaboration to develop new oncology drug delivery products using Kode™ Technology. Due to their public listing status, and confidential nature of the research, we cannot publicly name the other party. The second agreement is with a UK biopharmaceutical company developing an anti-cancer technology for the treatment of patients with solid tumors. They will use Kode™ Technology in the active pharmaceutical ingredient of their technology, which is due to enter the clinic in a Phase I study in 2016. We will release further details of the deal and technology after the company’s own announcement.

£21m deal: UK firm licenses cancer treatment technology from AUT’s Kode Biotech

By Chris Keall
Under the terms of the agreement, Kode may receive up to £21 million in development and sales milestones, plus royalties on net sales.

By Iain MacIntyre
Auckland University of Technology Professor and Biotechnology Research Institute (KODE Biotech) director Stephen Henry has been awarded the 2011 RJ Scott Medal for engineering science and technology work of great merit.